ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
Phase 2
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: Intravenous Placebo
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 438
- Registration Number
- NCT05070260
- Locations
- 🇺🇸
Nova Clinical Research, Bradenton, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Houston Methodist hospital, Houston, Texas, United States
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
Phase 2
Completed
- Conditions
- SARS-CoV InfectionAcute Respiratory Distress SyndromeCOVID-19ARDS
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT04659109
- Locations
- 🇫🇷
Hôpital de Hautepierre, Strasbourg, France
Acute Ischemic Stroke Interventional Study
Phase 1
Completed
- Conditions
- Acute Ischemic Stroke
- Interventions
- Other: Intravenous PlaceboDrug: Intravenous ACT017 1000 mg
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 160
- Registration Number
- NCT03803007
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Bordeaux,, Bordeau, France
© Copyright 2025. All Rights Reserved by MedPath